19,564 Shares in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Purchased by Squarepoint Ops LLC
Squarepoint Ops LLC bought a new stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 19,564 shares of the company’s stock, valued at approximately $52,000. Squarepoint Ops LLC owned approximately 0.07% of Aerovate Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). A number of other institutional investors and hedge funds have also made changes to their positions in AVTE. Braidwell LP bought a new stake in shares of Aerovate Therapeutics during the fourth quarter valued at approximately $3,817,000. ADAR1 Capital Management LLC boosted its stake in shares of Aerovate Therapeutics by 720.7% during the 4th quarter. ADAR1 Capital Management LLC now owns 928,016 shares of the company’s stock worth $2,459,000 after acquiring an additional 814,941 shares during the last quarter. Allostery Investments LP purchased a new position in shares of Aerovate Therapeutics during the 4th quarter valued at $2,254,000. Affinity Asset Advisors LLC lifted its stake in shares of Aerovate Therapeutics by 33.3% during the 4th quarter. Affinity Asset Advisors LLC now owns 800,000 shares of the company’s stock valued at $2,120,000 after buying an additional 200,000 shares in the last quarter. Finally, Jefferies Financial Group Inc. bought a new stake in Aerovate Therapeutics in the 4th quarter valued at $1,590,000. Aerovate Therapeutics Stock Performance Shares of NASDAQ AVTE opened at $7.71 on Wednesday. The company has a market cap of $223.47 million, a P/E ratio of -2.58 and a beta of 0.95. The firm’s fifty day moving average is $40.11 and its two-hundred day moving average is $71.98. Aerovate Therapeutics, Inc. has a 52-week low of $43.75 and a 52-week high of $884.98. Aerovate Therapeutics (NASDAQ:AVTE – Get Free Report) last posted its earnings results on Friday, April 25th. The company reported ($3.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($10.50) by $7.35. As a group, analysts forecast that Aerovate Therapeutics, Inc. will post -2.64 EPS for the current fiscal year. Aerovate Therapeutics Announces Dividend The company also recently declared a dividend, which was paid on Monday, April 28th. Investors of record on Friday, April 25th were paid a dividend of $84.00 per share. The ex-dividend date of this dividend was Tuesday, April 29th. Aerovate Therapeutics Profile (Free Report) Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Jun 11, 2025 | www.defenseworld.net
1-888-653-2347 
support@leadiq.com 
